Drugs / Propoxyphene napsylate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DARVON-N W/ ASA | — | 1971-09-09 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01133873 | Jun → Nov 2010 | — | Xanodyne Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Propoxyphene napsylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01133873 ↗ |
| Route | Oral | “Administered Orally” NCT01133873 ↗ |